Development of a Prognostic Nomogram for Patients with Lung Adenocarcinoma in the Stages I, II, and III Based on Immune Scores

References

• He Y, Liang D, Li D, et al. Incid ence and morta lity of laryngeal cancer in China, 2015. Chin J Cancer Res. 2020;32(1):10–17.
   PubMed Web of Science ®Google Scholar
• Fitzmaurice C, Abate D, Abbasi N; Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the global burden of disease study. JAMA Oncol. 2019;5(12):1749–1768. doi:10.1001/jamaoncol.2019.2996
   PubMed Web of Science ®Google Scholar
• Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S. Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience. 2016;10:648. doi:10.3332/ecancer.2016.648
   PubMed Web of Science ®Google Scholar
• Wang D, Gao Y, Zhang Y, Wang L, Chen G. Glypican-3 promotes cell proliferation and tumorigenesis through up-regulation of β-catenin expression in lung squamous cell carcinoma. Biosci Rep. 2019;39(6):BSR20181147. doi:10.1042/BSR20181147
   PubMed Web of Science ®Google Scholar
• Thunnissen E, Boers E, Heideman DA, et al. Correlation of immunohistochemical staining p63 and TTF-1 with EGFR and K-ras mutational spectrum and diagnostic reproducibility in non small cell lung carcinoma. Virchows Arch. 2012;461:629–638. doi:10.1007/s00428-012-1324-x
   PubMed Web of Science ®Google Scholar
• Sugiyama E, Togashi Y, Takeuchi Y, et al.Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR -mutated non–small cell lung cancer. Immunology. 2020;5(43):eaav3937.
   Web of Science ®Google Scholar
• Domagala-Kulawik J. The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res. 2015;4(2):177‐190. doi:10.3978/j.issn.2218-6751.2015.01.11
   PubMedGoogle Scholar
• Garon EB, Hellmann MD, Rizvi NA, et al. Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. JClin Oncol. 2019;37(28):2518‐2527. doi:10.1200/JCO.19.00934
   Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–1833. doi:10.1056/NEJMoa1606774
   PubMed Web of Science ®Google Scholar
• Ren S, Tian Q, Amar N. The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. Lung Cancer. 2018;125:115–120. doi:10.1016/j.lungcan.2018.09.004
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhang Q, Hu Y, et al. ImmunoScore signature: a prognostic and predictive tool in gastric cancer. Ann Surg. 2016. doi:10.1097/SLA.0000000000002116
   Web of Science ®Google Scholar
• Wang J, Li Y, Fu W, et al. Prognostic nomogram based on immune scores for breast cancer patients. Cancer Med. 2019;8:5214–5222. doi:10.1002/cam4.2428
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45:1113–1120. doi:10.1038/ng.2764
   PubMed Web of Science ®Google Scholar
• Oliveira-Mateos C, Sánchez-Castillo A, Soler M, et al. The transcribed pseudogene RPSAP52 enhances the oncofetal HMGA2-IGF2BP2-RAS axis through LIN28B-dependent and independent let-7 inhibition. Nat Commun. 2019;10(1):3979. doi:10.1038/s41467-019-11910-6
   PubMed Web of Science ®Google Scholar
• Miyashita M, Sasano H, Tamaki K, et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res. 2015;17(1):124. doi:10.1186/s13058-015-0632-x
   PubMed Web of Science ®Google Scholar
• Chen Y, Li W, Tang W, Yang X, Zhong W. [Observation - an favorable option for thoracic dissemination patients with lung adenocarcinoma or squamous carcinoma]. Zhongguo Fei Ai Za Zhi. 2018;21(4):303–309. Chinese. doi:10.3779/j.issn.1009-3419.2018.04.14
   PubMedGoogle Scholar
• Available from: https://medicine.yale.edu/lab/rimm/research/software/. Accessed November 19, 2021.
   Google Scholar
• Sugiyama E, Togashi Y, Takeuchi Y, et al. Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer. Sci Immunol. 2020;5. doi:10.1126/sciimmunol.aav3937
   PubMed Web of Science ®Google Scholar
• Anagnostou V, Niknafs N, Marrone K, et al. Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer. Nature Cancer. 2020;1:99–111. doi:10.1038/s43018-019-0008-8
   PubMedGoogle Scholar
• Yu Y, Zeng D, Ou Q, et al. Association of survival and immune-related biomarkers with immunotherapy in patients with non–small cell lung cancer. JAMA Netw Open. 2019;2(7):e196879. doi:10.1001/jamanetworkopen.2019.6879
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–128. doi:10.1126/science.aaa1348
   PubMed Web of Science ®Google Scholar
• Dai F, Liu L, Che G, et al. The number and microlocalization of tumor-associated immune cells are associated with patient’s survival time in non-small cell lung cancer. BMC Cancer. 2010;10(1):220. doi:10.1186/1471-2407-10-220
   PubMed Web of Science ®Google Scholar
• Pagès F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memoryT cells predict outcome in patients with early-stage colorectal cancer.J. Clin Oncol. 2009;27(35):5944–5951. doi:10.1200/JCO.2008.19.6147
   Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321‐330. doi:10.1038/nature21349
   Web of Science ®Google Scholar
• Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol. 1997;15(15):297–322. doi:10.1146/annurev.immunol.15.1.297
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martínez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Yan X, Jiao S. Roles of tumor-infiltrating lymphocytes in non-small cell lung cancer recurrence and metastasis: a meta analysis. Acta Academiae Medicinae Sinicae. 2015;37(4):406–414. doi:10.3881/j.issn.1000-503X.2015.04.007
   Google Scholar
• Fan H, Shao ZY, Xiao YY, et al. Survival analysis of patients with lung cancer in Shanghai. Chin J Tuberc Respir Dis. 1993;16(1):36–38.
   Google Scholar
• Gutierrez A, Suh R, Abtin F, Genshaft S, Brown K. Lung cancer screening. Semin Intervent Radiol. 2013;30(2):114–120. doi:10.1055/s-0033-1342951
   PubMed Web of Science ®Google Scholar
• He P, Gu X, Guan YB, et al. Clinicopathologic analysis of 37 cases of synchronous multiple primary lung cancer. Zhonghua Zhong Liu Fang Zhi Za Zhi. 2013;20(5):357–360.
   Google Scholar
• Li N, Ying J, Tao X, et al. P1.18-06 efficacy and safety of neoadjuvant PD-1 blockade with sintilimab in resectable non-small cell lung cancer. J Thorac Oncol. 2019;14(10):S627–S628. doi:10.1016/j.jtho.2019.08.1322
   Web of Science ®Google Scholar
• Herbst RS, Garon EB, Kim D-W, et al. Long-term survival in patients (pts) with advanced NSCLC in the KEYNOTE-010 study overall and in pts who completed two years of pembrolizumab (pembro). Ann Oncol. 2018;29(Supl.8):viii749–viii749. doi:10.1093/annonc/mdy424.075
   Google Scholar
• Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med. 2018;378:1976–1986. doi:10.1056/NEJMoa1716078
   PubMed Web of Science ®Google Scholar
• Forde PM, Brahmer JR, Kelly RJ. New strategies in lung cancer: epigenetic therapy for non-small cell lung cancer. Clin Cancer Res. 2014;20(9):2244–2248. doi:10.1158/1078-0432.ccr-13-2088
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Riely GJ. New pathologic classification of lung cancer: relevance for clinical practice and clinical trials. J Clin Oncol. 2013;31:992–1001.
   PubMed Web of Science ®Google Scholar